Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.

MLA

Srkalovic, Gordan, et al. “Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology, vol. 8, Dec. 2024, pp. 1–13. EBSCOhost, https://doi.org/10.1200/PO.24.00026.

APA

Srkalovic, G., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Ahn, E. R., Brouse, G., Chan, J., Mehmi, I., Khalil, M., Duvivier, H. L., Gaba, A., Leuva, H., Thota, R., Yost, K. J., Grantham, G. N., Gregory, A., Hinshaw, D. C., Halabi, S., & Schilsky, R. L. (2024). Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 8, 1–13. https://doi.org/10.1200/PO.24.00026

Chicago

Srkalovic, Gordan, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene R. Ahn, Gregory Brouse, John Chan, et al. 2024. “Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology 8 (December): 1–13. doi:10.1200/PO.24.00026.